



**ICMC**

International Center for  
Multimorbidity and  
Complexity in Medicine  
[www.multimorbidity.org](http://www.multimorbidity.org)

# **Patient Health Questionnaire (PHQ-9)**

**English Version**



## Patient Health Questionnaire (PHQ-9)

<i>Over the <u>last 2 weeks</u>, how often have you been bothered by any of the following problems?</i>	Not at all	Several days	More than half the days	Nearly every day
1. Little interest or pleasure in doing things	0	1	2	3
2. Feeling down, depressed or hopeless	0	1	2	3
3. Trouble falling or staying asleep, or sleeping too much	0	1	2	3
4. Feeling tired or having little energy	0	1	2	3
5. Poor appetite or overeating	0	1	2	3
6. Feeling bad about yourself or that you are a failure or have let yourself or your family down	0	1	2	3
7. Trouble concentrating on things, such as reading the newspaper or watching television	0	1	2	3
8. Moving or speaking so slowly that other people could have noticed, or the opposite – being so fidgety or restless that you have been moving around a lot more than usual	0	1	2	3
9. Thoughts that you would be better off dead, or of hurting yourself	0	1	2	3
<b>Column totals:</b>	_____ +	_____ +	_____ +	_____

**Total score:** \_\_\_\_\_

### Patient Health Questionnaire (PHQ-9)

10. If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?

**Not difficult at  
all**

**Somewhat  
difficult**

**Very  
difficult**

**Extremely  
difficult**

## PHQ-9 Patient Depression Questionnaire (PHQ-9)

Description.....	5
Structure and Application.....	5
Scoring and Interpretation .....	6
Reccomended Cut-off Scores .....	6
Diagnostic Cut-Point for MDD .....	6
Item 9 and Suicide Risk.....	6
Psychometric Properties.....	6
Key Research Findings .....	7
Clinical Applicability & Limitations .....	7
Advantages .....	7
Limitations .....	7
References .....	8

### Description

The **Patient Health Questionnaire-9 (PHQ-9)** is a widely used **9-item self-report screening tool** for **major depressive disorder (MDD)** and **depressive symptom severity**. It aligns with the **diagnostic criteria for depression** in the **DSM-5** and is used in **primary care, mental health, and research settings** to identify and monitor depression over time.

The PHQ-9 serves **two primary purposes**:

1. **Screening for Major Depressive Disorder (MDD):** A score-based algorithm helps detect probable MDD.
2. **Assessing Depression Severity:** The total score indicates the degree of depression severity, ranging from **minimal to severe depression**.

### Structure and Application

The PHQ-9 consists of nine items, each corresponding to one of the nine DSM-5 criteria for MDD. The questions assess the frequency of depressive symptoms over the past two weeks. Responses are rated on a 4-point Likert scale:

Response Option	Score
Not at all	0
Several days	1
More than half the days	2
Nearly every day	3

## Scoring and Interpretation

The total **PHQ-9** score is obtained by summing the responses. A **higher score indicates more severe depressive symptoms**. Additionally, a **tenth question** assesses whether the symptoms lead to **impairments in daily life** (Spitzer et al., 1999).

## Reccomended Cut-off Scores

Score	Depression Severity	Clinical Interpretation
0-4	Minimal depression	No intervention needed
5-9	Mild depression	Monitor; consider follow-up
10-14	Moderate depression	Further assessment; possible treatment
15-19	Moderately severe depression	Active treatment recommended
20-27	Severe depression	Immediate intervention needed

## Diagnostic Cut-Point for MDD

- A **score of  $\geq 10$**  is considered a **sensitive and specific cut-off** for **major depressive disorder**.
- A score  $\geq 15$  strongly indicates the presence of clinically significant depression.

## Item 9 and Suicide Risk

- **Item 9** ("Thoughts that you would be better off dead or of hurting yourself in some way") assesses **suicidal ideation**.
- Any response  $\geq 1$  (i.e., "Several days" or more) warrants **further suicide risk assessment** and clinical intervention.

## Psychometric Properties

The **PHQ-9** demonstrates high internal consistency (Cronbach's alpha  $> 0.8$ ) and good test-retest reliability. Studies show high sensitivity and specificity for detecting major depression, making the **PHQ-9** a reliable instrument.

The key diagnostic properties of the **PHQ-9** are summarized below:

Metric	Value
<b>Sensitivity (cut-off <math>\geq 10</math>)</b>	<b>0.88</b> (88%) (Kroenke et al., 2001)
<b>Specificity (cut-off <math>\geq 10</math>)</b>	<b>0.88</b> (88%) (Kroenke et al., 2001)
<b>Positive Predictive Value (PPV)</b>	<b>0.75–0.85</b> , depending on population prevalence (Manea et al., 2012)
<b>Negative Predictive Value (NPV)</b>	<b>0.92</b> (92%) (Manea et al., 2012)
<b>Internal Consistency (Cronbachs Alpha)</b>	<b>0.86–0.89</b> (Excellent reliability) (Kroenke et al., 2001)

## Key Research Findings

- A **PHQ-9 score of  $\geq 10$**  has **88% sensitivity and specificity** for **MDD diagnosis**, making it one of the most accurate **brief depression screening tools** (Kroenke et al., 2001).
- The PHQ-9 performs **comparably** to **longer depression measures**, such as the **Beck Depression Inventory (BDI-II)**, while being **shorter and more practical** for routine screening (Manea et al., 2012).
- The **PHQ-9 is validated in diverse populations**, including **adolescents, elderly adults, and different ethnic groups** (Levis et al., 2019).

## Clinical Applicability & Limitations

The **PHQ-9** is frequently used in **primary care, psychiatry, and epidemiological** studies. Its simplicity makes it an efficient **screening tool**. However, **additional clinical assessments are necessary, especially for high scores** (Spitzer et al., 1999).

### Advantages

- **Brief and Easy to Administer:** Takes **2-5 minutes** to complete.
- **Highly Validated:** Shows **high sensitivity and specificity** for MDD.
- **Useful for Symptom Monitoring:** Can track **treatment progress** over time.
- **Validated Across Multiple Settings:** Effective in **primary care, psychiatry, and community samples**.

### Limitations

- **Not a Standalone Diagnostic Tool:** Requires **further clinical assessment** for formal MDD diagnosis.
- **Risk of Overdiagnosis:** In some settings, **false positives** may lead to **unnecessary treatment**.
- **Item 9 Requires Immediate Attention:** Suicide-related responses need **urgent risk assessment**.

## References

1. **Kroenke K, Spitzer RL, Williams JB.** The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. PMID: 11556941; PMCID: PMC1495268.
2. **Manea L, Gilbody S, McMillan D.** Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. *CMAJ.* 2012 Feb 21;184(3):E191-6. doi: 10.1503/cmaj.110829. Epub 2011 Dec 19. PMID: 22184363; PMCID: PMC3281183.
3. **Levis B, Benedetti A, Thombs BD;** Depression Screening Data (DEPRESSD) Collaboration. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. *BMJ.* 2019 Apr 9;365:l1476. doi: 10.1136/bmj.l1476. Erratum in: *BMJ.* 2019 Apr 12;365:l1781. doi: 10.1136/bmj.l1781. PMID: 30967483; PMCID: PMC6454318.

Developed by Spitzer, Kroenke, and Williams, the PHQ-9 is widely used in both clinical and research settings. It is not patent protected, though the published text and scoring instructions are subject to copyright.